AML

Advertisement
Rob DillardASCO 2022 | August 30, 2023
A recent analysis shows that shallow whole-genome sequencing (sWGS) is an accurate, convenient, and cost-effective ...
Read More
DocWire News EditorsOncology | April 13, 2023
The Journey of Roe Roe: A Brave Girl Battling Leukemia ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 30, 2023
According to results from a phase I/II study, more than 90% of older and high-risk patients with newly diagnosed acute ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 13, 2023
According to research presented during the 2021 ASH Annual Meeting, induction and consolidation therapy comprising ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 30, 2023
In an open-label, multicenter study presented at the 2021 ASH Annual Meeting, the combination of sabatolimab and ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 13, 2023
The combination of magrolimab with venetoclax and azacitidine was considered safe and highly effective in older and ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 30, 2023
In in vitro and in vivo preclinical models, the combination of magrolimab with venetoclax plus azacitidine increased ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 30, 2023
For older and high-risk patients with newly diagnosed acute myeloid leukemia (AML), the treatment combination of ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 24, 2023
Sabatolimab, an immunotherapeutic therapy targeting TIM-3 on immune and myeloid cells, was well-tolerated and led to ...
Rebecca AraujoOncology | August 30, 2023
Each week on DocWire News, editors bring you the latest hematology and oncology news and research. In case you missed ...
Rob DillardOncology | April 13, 2023
Brian Jonas, MD, PhD, FACP sat down with DocWire News Discusses FDA Approval of Venclexta® in combination with with ...
Rebecca AraujoOncology | April 13, 2023
Researchers Identify New Therapeutic Target for Prostate Cancer Treatment Resistance ...
Rebecca AraujoOncology | April 13, 2023
According to data from a new study, adolescent and young adult (AYA) patients who were treated for acute myeloid ...
Rebecca AraujoOncology | April 13, 2023
Participants in the Leukemia & Lymphoma Society’s (LLS) precision medicine clinical trial for acute myeloid ...
Rob DillardConference Coverage | April 13, 2023
A simple electronic tool may provide valuable insight into patient understanding of acute myelogenous leukemia (AML) to ...
Kerri FitzgeraldOncology | April 13, 2023
Gilteritinib significantly improved survival among patients with relapsed/refractory FLT3-mutated acute myeloid ...
Rob DillardOncology | March 31, 2023
Leukemia, which derives from the Greek words leukos (white) and haima (blood) is a form of cancer that affects the blood ...
DocWire News EditorsOncology | April 13, 2023
A research team from the Cold Spring Harbor Laboratory in New York have recently identified two cell mutations that work ...
DocWire News EditorsOncology | April 13, 2023
A specific group of antihistamine medications can eradicate leukaemic stem cells, according to research from the ...
Advertisement
Advertisement
Advertisement
Latest News

March 14, 2025